Merck Sharp & Dohme Corp. v. ScieGen Pharmaceuticals, Inc. et al
| Merck Sharp & Dohme Corp. |
| ScieGen Pharmaceuticals, Inc. and Bactolac Pharmaceutical Inc. |
| 1:2021cv01616 |
| November 15, 2021 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on November 22, 2021. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 11 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,326,708. (Attachments: #1 Judgment)(nms) |
| Filing 10 CONSENT JUDGMENT. Signed by Judge Richard G. Andrews on 11/22/2021. (nms) |
| Filing 9 PROPOSED Consent Judgment, by Merck Sharp & Dohme Corp.. (Joyce, Alexandra) Modified on 11/22/2021 (nms). |
| Filing 8 MOTION for Pro Hac Vice Appearance of Attorney Robert Silver - filed by Bactolac Pharmaceutical Inc., ScieGen Pharmaceuticals, Inc.. (Rogowski, Patricia) |
| Filing 7 NOTICE of Appearance by Patricia Smink Rogowski on behalf of All Defendants (Rogowski, Patricia) |
SO ORDERED, re #8 MOTION for Pro Hac Vice Appearance of Attorney Robert Silver, filed by Bactolac Pharmaceutical Inc., ScieGen Pharmaceuticals, Inc.. Signed by Judge Richard G. Andrews on 11/19/2021. (nms)
|
| Pro Hac Vice Attorney Robert S. Silver for Bactolac Pharmaceutical Inc. and ScieGen Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) |
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (nms) |
| Filing 6 Summons Issued with Magistrate Consent Notice attached as to Bactolac Pharmaceutical Inc. on 11/16/2021; ScieGen Pharmaceuticals, Inc. on 11/16/2021. (Attachments: #1 Summons Issued)(myr) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Merck & Co., Inc. for Merck Sharp & Dohme Corp. filed by Merck Sharp & Dohme Corp. (myr) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,326,708. (myr) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No Earlier than October 6, 2021. Date of Expiration of Patent: November 24, 2026 (May 24, 2027 pediatric exclusivity expiration).Thirty Month Stay Deadline: No Earlier than 4/6/2024. (myr) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (myr) |
| Filing 1 COMPLAINT filed against Bactolac Pharmaceutical Inc., ScieGen Pharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3743365.) - filed by Merck Sharp & Dohme Corp. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet)(myr) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
